243641-39-6

Usage

Uses

Used in Pharmaceutical Industry:
1,8-Naphthyridine-2-ethanol, 1,5,6,7-tetrahydrois used as a key intermediate in the synthesis of integrin targeting ligands for the treatment and prevention of diseases. Integrins are cell surface receptors that play a crucial role in various biological processes, including cell adhesion, migration, and signaling. By targeting these receptors, the compound can potentially be used to develop therapeutic agents for a range of conditions, such as cancer, autoimmune disorders, and inflammatory diseases.

Upstream product

• 445490-78-8 tert-butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(12H)-carboxylate 
• 721920-80-5 ethyl (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)acetate 
• 339536-82-2 [1,8]naphthyridin-2-yl-acetic acid ethyl ester 
• 7521-41-7 2-Aminonicotinaldehyde 
• 1569-16-0 2-methyl-[1,8]naphthyridine 
• 274676-47-0 7-methyl-1,2,3,4-tetrahydro-[1,8]naphthyridine 
• 243641-37-4 tert-butyl 7-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate 
• 243641-38-5 7-ethoxycarbonylmethyl-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 721920-79-2 (E)-1-ethoxy-2-(1,8-naphthyridin-2-yl)ethenol 

Downstream Products

• 853401-05-5 ethyl (2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}cyclopropyl)acetate 
• 959993-32-9 2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethanol 

Relevant academic research and scientific papers

INTEGRIN ANTAGONISTS

The present disclosure provides pharmaceutical agents, including those of the formula:(I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Meth

2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists

We describe a series of pyrazole and isoxazole analogs as antagonists of the αvβ3 receptor. Compounds showed low to sub-nanomolar potency against αvβ3, as well as good selectivity against αIIbβ3

NOVEL PROCESSES FOR THE SYNTHESIS OF CYCLOPROPYL COMPOUNDS

This invention relates to processes for the preparation of cyclopropyl compounds of Formula: (I) wherein: x is an integer selected from the group consisting of 0, 1 and 2; R and R are independently selected from the group consisting of H, C1-C6 alkyl, and halo; and R, R, R, R and R are independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, and halo.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES

The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the α Vβ5 integrin without significantly inhibitin

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

VITRONECTIN RECEPTOR ANTAGONISTS

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein R is Het- or Ar; R is formula (a) or formula (b); or a pharmaceutically acceptable salt thereof.